SEC Form 4 · accession 0001209191-15-053915
KYNTRA BIO, INC. · KYNB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jorma Routti
Director
Period of report
Nov 19, 2014
Accepted (ET)
Jun 16, 2015 · 5:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000921299
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 19, 2014 | C | 39,840 | — | A | 107,840 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series B Preferred Stock of Fibrogen Europe OyF1,F2 | — | Nov 19, 2014 | C | 60,000 | D | — | — | Common Stock | 39,840 | 0 | D |
Explanation of responses
- F1Each share of Fibrogen Europe Oy's Series B Preferred Stock automatically converted into 0.664 of a share of the issuer's common stock immediately prior to the closing of the issuer's initial public offering.
- F2Not applicable.